Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Vaderis Therapeutics

Request full access

Oral AKT inhibitor engasertib for hereditary hemorrhagic telangiectasia

Basel, SwitzerlandFounded 2020Biotech & Life Sciences

About Vaderis Therapeutics

Vaderis Therapeutics is a Basel clinical-stage biopharmaceutical company developing targeted therapies for rare vascular diseases, led by President and CEO Azmi Nabulsi. Its lead candidate engasertib (VAD044) is an investigational once-daily oral allosteric AKT1/2 inhibitor for hereditary hemorrhagic telangiectasia (HHT), a rare genetic vascular disorder with no approved therapies worldwide. In August 2026 Vaderis closed an oversubscribed $152 million Series B co-led by Life Sciences at Goldman Sachs Alternatives and TCGX, with Omega Funds, EQT Life Sciences, Perceptive Advisors, Kalehua Capital and existing investors Medicxi and Droia, and initiated the global Phase 3 HEROIC study. Capital is intended to fund operations through potential U.S. regulatory approval. Sources: PR Newswire 11 Aug 2026; Fierce Biotech.

Source: Dealroom company data

At a glance

Status
Operational
Employees
22
Open positions
None listed
Dealroom signal
93.0/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Disease, Biotech and Pharma, Hard Tech, DT and LS, science-based, Swiss DT Biotech
Business model
Manufacturing
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES B✓Equity / VC Aug 2026 $152M $608M Omega Funds · Perceptive Advisors · Medicxi · EQT Life Sciences ↗
LATE VC✓Equity / VC Jan 2020 $17M $66M Medicxi ↗
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Vaderis Therapeutics website traffic

Latest recorded traffic for Vaderis Therapeutics is 1.3K monthly website visits, down 59.4% over the last three months. Vaderis Therapeutics's team grew 37.5% over the past year.

Latest monthly visits1.3K 3-month web change-59.4% 1-year team growth+37.5%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Vaderis Therapeutics in the Basel ecosystem

Live from Dealroom

The Vaderis Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A6 investors entered at this stage

  • TCGX
  • Omega Funds
  • Perceptive Advisors
  • EQT Life Sciences
  • Droia Oncology Ventures
  • Kalehua Capital Management

Series B and later1 investor entered at this stage

  • Medicxi
Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

See Vaderis Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.